Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Entourage Health Corp V.ENTG

Alternate Symbol(s):  ETRGF

Entourage Health Corp. is a Canada-based license holder producing and distributing cannabis products for both the medical and adult-use markets. The Company owns and operates a 26,000 square feet indoor facility in Aylmer, Ontario (the Aylmer Facility), specializing in product development and fulfillment for both adult-use and medical cannabis. The Company is focused on building a portfolio of brands in the Canadian market, including its brand Color Cannabis, mainstream brand Saturday Cannabis, medical cannabis product brand Starseed Medicinal and its craft cannabis brand Syndicate Cannabis. The Company produces a diverse portfolio of cannabis and cannabis derivative products, including oils, capsules, soft chews, topicals, beverages and vapes, for sale in both the medical and adult-use markets across Canada. Its elite adult-use product portfolio also includes Dime Bag a pre-roll offering, sold across eight provincial distribution agencies.


TSXV:ENTG - Post by User

Post by HappyFlowers25on Mar 23, 2021 2:50pm
228 Views
Post# 32859525

On Sedar, March 8, 2021, Final Shot Orm Propectus, page 13,

On Sedar, March 8, 2021, Final Shot Orm Propectus, page 13, On Sedar, March 8, 2021, Final Shot Orm Propectus, page 13, Weedmd said: Principal Purposes, Objectives, Milestones------------------------------- One of the Company's primary business objectives is for the Company to become cash flow positive by the end of the 2021 fiscal year. The Company has taken active steps to reach this goal including streaming processes and engaging a third-party consultant to assist with financial planning and adopting certain efficiencies. The Company believes that in order to meet this objective it must increase revenues from sales of the Company's products during the 2021 fiscal year. In order to increase sales, the Company plans to allocate funds to increased marketing and sales efforts, the expansion of product lines and operational capacity and output. While the Company had initially contemplated such amounts being expended over the next 12 to 18 months, with the net proceeds from the Offering, the timing of such initiatives can be accelerated such that the Company expects to see results of such initiatives during the 2021 fiscal year . The specific amounts to be allocated to each of these activities has been estimated as follows:------------------------------------------- Milestones Sales and Marketing Initiatives for Q2-Q4 2021:$ 7,098,000 --------- Increased Operational Capacity :$ 4,352,000 ------------------ Product Development $ 2,250,000 ----------------- (1) (4) Total : $ 13,700,000
<< Previous
Bullboard Posts
Next >>